Follicular Lymphoma News and Research

RSS
Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.
Study shows promising results for treating lymphoma patients with immune cell therapy

Study shows promising results for treating lymphoma patients with immune cell therapy

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Bacterium that causes Q fever associated with increased risk of lymphoma

Bacterium that causes Q fever associated with increased risk of lymphoma

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Two years may be a more practical survival goal for patients with follicular lymphoma

Two years may be a more practical survival goal for patients with follicular lymphoma

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing can detect maternal cancer at early stage

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma